Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma
Toulsie Ramtohul(Université Paris Sciences et Lettres), Vincent Servois(Université Paris Sciences et Lettres), Axel Cohen(Université Paris Sciences et Lettres), Denis Malaise(Inserm), Nathalie Cassoux(Institut Curie), Pascale Mariani(Université Paris Sciences et Lettres), Sophie Gardrat(Institut Curie), Manuel Rodrigues(Inserm), Luc Cabel(Université de Versailles Saint-Quentin-en-Yvelines), Livia Lumbroso-Le Rouïc(Université Paris Sciences et Lettres), Gaëlle Pierron(Institut Curie), Sophie Piperno‐Neumann(Institut Curie)
Cited by 8
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869